Cesca Therapeutics partnership positive, says H.C. Wainwright After Cesca (KOOL) announced an expanded collaboration with pan Asia-Pacific hospital owner Fortis Healthcare, H.C. Wainwright believes the announcement is "excellent news." The firm thinks the deal gives Cesca a stronger foothold in Asia and could enable its new cell therapy treatments to be approved more quickly. The firm views the stock as undervalued and keeps a $5 price target and Buy rating on the shares.
Cesca Therapeutics files IDE application for no-option critical limb ischemia Cesca Therapeutics has submitted an investigational device exemption application to the FDA for a pivotal multicenter study of the company's SurgWerks-CLI and VXP System for treating advanced stages of no-option lower limb critical limb ischemia. The IDE application is the result of two prior positive pilot and feasibility studies conducted in Italy and India, respectively, and collaborative pre-IDE feedback from the U.S. FDA. The primary endpoint is major amputation free survival at 12 months following enrollment.